TrumpRx Expands Discount Drug Access With 600 Generic Medications 
Should I take zinc or eat oysters to ward off colds, boost my immune system or improve fertility? 
SpaceX Targets Thursday Launch for Starship's 13th Test Flight After Last-Minute Delay 
Ryanair Warns Summer Airfares May Stay Lower as Quarterly Profit Misses Estimates 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Belimo H1 Sales Surge as AI Data Center Cooling Drives More Than Half of Growth 
Gold Price Jumps Near 2% Above $4,080 as Middle East Tensions Lift Safe-Haven Demand 
European Stocks Slip as Earnings, UK Inflation and ECB Decision Keep Investors on Edge 
Alaska Air Q3 Outlook Misses Estimates as Higher Fuel Costs Weigh on Profit Forecast 
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak 
Lockheed Martin Unveils Lower-Cost Patriot ACE Interceptor to Meet Rising Air Defense Demand 
Tesla Stock Outlook: Strong EV Sales Boost Earnings, but AI Projects Drive Long-Term Value 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Bank of America Says These Overlooked AI Stocks Could Be the Next Winners 
Trump Announces 100% Tariff on Generic Drug Imports Starting in 2028 
US Stock Exchanges Face Earnings Test as Trading Boom Meets Crypto Competition 
KKR, AEW Seek China Property Sales as Commercial Real Estate Slump Deepens 
Novavax raised doubts about the feasibility of continuing its business after struggles in rolling out its coronavirus jab although it has enough money to fund operations.
The COVID-19 vaccine maker, which described the situation as "subject to significant uncertainty," also announced plans to cut spending
On Tuesday, the company reported a loss of $182 million in the fourth quarter, after posting weaker sales than expected at $357 million.
Consequently, Novavax shares plummeted 25 percent in extended trading.
Novavax is currently gearing up for a fall vaccination campaign and said it plans to focus on delivering an updated COVID-19 vaccine.
The Maryland-based Novavax was an early frontrunner in the global vaccine race but fell behind after being hit by manufacturing and regulatory delays.
The company faced delays in regulatory submissions for its jab, which was only authorized in the US in July last year.
Before that, it received authorization from the European Union, United Kingdom, Canada, and Australia.
